Potassium (K+) channels play a critical role in regulating neuronal excitability, a fundamental feature of pain. The opening of K+ channels leads to hyperpolarization of the cell membrane, which results in a decrease of cell excitability. In the nociceptive pathways, K+ channels are involved in a number of processes within the nervous system, including neuronal depolarization, axonal conduction, and neurotransmitter release. As a consequence of the role played by K+ channels in the regulation of the nociceptive system and that K+ channel opening is involved in the antinociception induced by numerous analgesic drugs they have begun to be considered as direct targets for the development of new antinociceptive therapies. A limited number of potential K+ channels have, so far, been identified as targets for the development of antinociceptive therapies. This review considers the potential of selective modulators of KCNQ, KATP, GIRK, Twopore domain K+ channels, or KCa channels as novel therapeutic approaches to pain. Structure-activity relationship (SAR) studies to identify K+ channel selective modulators to target neuroexcitability and pain have, however, been limited to modulators KCNQ channels. The scope of the field of K+ channel modulators is just emerging but demonstrates promise for novel therapeutics in the management of pain.
No takes yet. Share an insight, caveat, or question.
Kim Lawson (2006) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: